A combination of BRAF and MEK inhibitors plus immunotherapy improved progression-free but not overall survival, compared to dual immune checkpoint blockade.

The Australian company is betting the radionuclide could be an option for patients with HER2-expressing solid tumors who can't tolerate other treatments.

The French company is designing a Phase IIb program to validate the biomarker, which could identify the 30 percent of patients likely to respond to the antibody.

At ASCO, researchers presented results of Phase I trials evaluating combinations of KRAS G12C inhibitors, EGFR inhibitors, and chemotherapy in colorectal cancer.

Researchers are trying to better understand how co-mutations and PD-L1 expression impact response to single-agent KRAS G12C ...

A combination of Enhertu and Perjeta nearly doubled progression-free survival compared to standard therapy in data presented ...

Gilead has already announced intentions to bring the data, which demonstrated a 35 percent reduction in risk of progression ...

Researchers at ASCO reviewing data from the ATOMIC trial said they will change practice based on the results but questioned ...

Investigators aim to establish an optimal dose and explore CER-1236's safety and preliminary anti-tumor activity.

The latest readout from the BREAKWATER study showed "unprecedented" median overall survival of 30.3 months for ...

UniQure said it has aligned with the FDA on components of a statistical analysis plan for a registrational trial of AMT-130.

Researchers at ASCO provided a look at DB-1310 and iza-bren in genomically altered NSCLC, amid an overall survival miss for ...